Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q2 FY26 results · Jul–Sep 2025
Astec LifeSciences reported revenue from operations of ₹73.72 crore (down 25.2% from Q2 FY25) and net loss of ₹24.42 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 73.72 | 98.55 | −25.2% | 91.08 | −19.1% |
| Other income | 1.12 | 2.00 | −44.2% | 0.51 | +120.3% |
| Total income | 74.84 | 100.54 | −25.6% | 91.59 | −18.3% |
| Profit before tax | (24.41) | (38.54) | Loss narrowed | (33.02) | Loss narrowed |
| Net profit for the period | (24.42) | (38.55) | Loss narrowed | (33.03) | Loss narrowed |
| Attributable to shareholders of the company | (24.43) | (38.56) | Loss narrowed | (33.04) | Loss narrowed |
| EPS, basic (₹) | (11.35) | (19.66) | not comparable | (16.85) | not comparable |
| Net margin (%) | -33.1 | -39.1 | -36.3 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 73.72 | 98.55 | −25.2% | 91.08 | −19.1% |
| Other income | 1.09 | 1.98 | −44.8% | 0.49 | +124.9% |
| Total income | 74.81 | 100.53 | −25.6% | 91.57 | −18.3% |
| Profit before tax | (24.45) | (38.57) | Loss narrowed | (33.06) | Loss narrowed |
| Net profit for the period | (24.45) | (38.57) | Loss narrowed | (33.06) | Loss narrowed |
| EPS, basic (₹) | (11.39) | (19.67) | not comparable | (16.86) | not comparable |
| Net margin (%) | -33.2 | -39.1 | -36.3 |
Consolidated
- Filed with BSE
- 29 Oct 2025, 23:00 IST
- Board meeting
- 29 Oct 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Oct 2025, 23:00 IST
- Board meeting
- 29 Oct 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE